A Phase 1/2 Multi-center Investigation of ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 26 Jul 2019
Price : $35 *
At a glance
- Drugs Sirolimus (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AADi
- 20 Feb 2019 Planned number of patients changed from 43 to 58.
- 19 Jan 2019 Trial design presented at the 2019 Gastrointestinal Cancers Symposium
- 18 Jul 2018 Status changed from not yet recruiting to recruiting.